Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication

키워드

참고문헌 (18)

1. Jacobsen SJ, "Natural history of benign prostatic hyperplasia", Urology, 58(6 Suppl 1), pp.5~16 (2001)
2. Emberton M, "Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials", BJU Int, 102, pp.981~986 (2008)
3. Emberton M, "Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management", Int J Clin Pract, 62, pp.1076~1086 (2008)
4. Djavan B, "A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction", Eur Urol, 36, pp.1~13 (1999)
5. Lepor H, "The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group", J Urol, 160, pp.1358~1367 (1998)
6. Roehrborn CG, "Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a fouryear, randomized trial comparing finasteride versus placebo. PLESS Study Group", Urology, 54, pp.662~669 (1999)
7. Gormley GJ, "The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group", N Engl J Med, 327, pp.1185~1191 (1992)
8. McConnell JD, "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia", N Engl J Med, 349, pp.2387~2398 (2003)
9. Roehrborn CG, "The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study", Eur Urol, 57, pp.123~131 (2010)
10. McVary KT, "Update on AUA guideline on the management of benign prostatic hyperplasia", J Urol, 185, pp.1793~1803 (2011)
11. Oelke M, "EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction", Eur Urol, 64, pp.118~140 (2013)
12. Emberton M, "Risk stratification for benign prostatic hyperplasia (BPH) treatment", BJU Int, 107, pp.876~880 (2011)
13. Madersbacher S, "The long-term outcome of medical therapy for BPH", Eur Urol, 51, pp.1522~1533 (2007)
14. Roehrborn CG, "Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies", BJU Int, 96, pp.572~577 (2005)
15. Descazeaud A, "Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia", Prog Urol, 25, pp.115~127 (2015)
16. Cindolo L, "Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study", Eur Urol, 68, pp.418~425 (2015)
17. Liu CC, "Relationships between American Urological Association symptom index, prostate volume, and disease-specific quality of life question in patients with benign prostatic hyperplasia", Kaohsiung J Med Sci, 20, pp.273~278 (2004)
18. Koh JS, "Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia", Int J Clin Pract, 68, pp.197~202 (2014)

관련 논문AI추천